IS1843B - Aðferð til að framleiða kristallaða amifostínblöndu ásamt skammtaformum af kristölluðu amifostíni - Google Patents

Aðferð til að framleiða kristallaða amifostínblöndu ásamt skammtaformum af kristölluðu amifostíni

Info

Publication number
IS1843B
IS1843B IS4060A IS4060A IS1843B IS 1843 B IS1843 B IS 1843B IS 4060 A IS4060 A IS 4060A IS 4060 A IS4060 A IS 4060A IS 1843 B IS1843 B IS 1843B
Authority
IS
Iceland
Prior art keywords
crystalline amifostine
amifostine
present
crystalline
dosage forms
Prior art date
Application number
IS4060A
Other languages
English (en)
Other versions
IS4060A (is
Inventor
E. Kennedy Paul
A. Rajewski Roger
M. Baldoni John
Original Assignee
Medimmune Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26795942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS1843(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/099,298 external-priority patent/US5424471A/en
Application filed by Medimmune Oncology, Inc. filed Critical Medimmune Oncology, Inc.
Publication of IS4060A publication Critical patent/IS4060A/is
Publication of IS1843B publication Critical patent/IS1843B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
IS4060A 1992-07-31 1993-07-30 Aðferð til að framleiða kristallaða amifostínblöndu ásamt skammtaformum af kristölluðu amifostíni IS1843B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92292992A 1992-07-31 1992-07-31
US08/099,298 US5424471A (en) 1992-07-31 1993-07-29 Crystalline amifostine compositions and methods of the preparation and use of same

Publications (2)

Publication Number Publication Date
IS4060A IS4060A (is) 1994-02-01
IS1843B true IS1843B (is) 2003-01-30

Family

ID=26795942

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4060A IS1843B (is) 1992-07-31 1993-07-30 Aðferð til að framleiða kristallaða amifostínblöndu ásamt skammtaformum af kristölluðu amifostíni

Country Status (23)

Country Link
US (1) US5591731A (is)
EP (1) EP0655917B1 (is)
JP (1) JP3503943B2 (is)
CN (2) CN1070370C (is)
AT (1) ATE261729T1 (is)
AU (1) AU681858B2 (is)
CA (1) CA2120133C (is)
CZ (1) CZ284417B6 (is)
DE (1) DE69333453T2 (is)
DK (1) DK0655917T3 (is)
ES (1) ES2215992T3 (is)
HK (1) HK1010692A1 (is)
HU (1) HU227122B1 (is)
IL (1) IL106540A (is)
IS (1) IS1843B (is)
MX (1) MX9304627A (is)
NO (2) NO309636B1 (is)
NZ (1) NZ255182A (is)
PL (1) PL178463B1 (is)
PT (1) PT655917E (is)
RU (1) RU2125880C1 (is)
SG (1) SG47101A1 (is)
SK (1) SK283318B6 (is)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
CN1148192C (zh) * 2000-10-19 2004-05-05 南京振中生物工程有限公司 细胞保护剂氨磷汀制剂及其制备方法
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
CN1305478C (zh) * 2004-05-12 2007-03-21 天津市资福医药科技开发有限公司 氨磷汀冻干制剂及其制备方法
PT3424932T (pt) * 2005-02-16 2021-05-19 Anacor Pharmaceuticals Inc Boronoftalidas para utilização terapêutica
WO2007047315A1 (en) * 2005-10-20 2007-04-26 Albemarle Corporation Amifostine dihydrate crystalline composition
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2008131324A (ru) * 2005-12-30 2010-02-10 Анакор Фармасьютикалз, Инк. (Us) Борсодержащие малые молекулы
ES2728455T3 (es) 2006-02-16 2019-10-24 Anacor Pharmaceuticals Inc Moléculas pequeñas que contienen boro como agentes antiinflamatorios
US9585849B2 (en) * 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
US20090239817A1 (en) * 2006-04-17 2009-09-24 Goverment Of The United States Of America, As Represented By The Secretary, Dept Of Health Organic thiophosphate antiretroviral agents
WO2008060441A2 (en) * 2006-11-09 2008-05-22 Scidose Llc Stable amifostine liquid concentrate
KR101672511B1 (ko) 2008-03-06 2016-11-03 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
WO2009140309A2 (en) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
CN101412732B (zh) * 2008-09-02 2011-09-07 大连美罗药业股份有限公司 三水合3-氨基丙基胺乙基硫代磷酸高纯稳定晶体及其制备方法
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
CN102256494A (zh) * 2008-12-17 2011-11-23 阿纳科制药公司 (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
MX2012001156A (es) * 2009-07-28 2012-05-08 Anacor Pharmaceuticals Inc Moleculas que contienen boro trisustituidas.
WO2011019618A1 (en) * 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
MX2012002031A (es) * 2009-08-19 2012-07-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2501234B1 (en) * 2009-11-20 2017-09-13 Tonix Pharma Holdings Limited Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
EP2613788B1 (en) 2010-09-07 2017-06-21 Anacor Pharmaceuticals, Inc. Benzoxaborole derivatives for treating bacterial infections
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物
CN102286020A (zh) * 2011-07-11 2011-12-21 大连美罗大药厂 一水合3-氨基丙基胺乙基硫代磷酸的制备方法
US10117936B2 (en) 2013-03-15 2018-11-06 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US20160143926A1 (en) * 2013-06-18 2016-05-26 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
CA2963458C (en) * 2014-10-02 2023-09-26 Cytosorbents Corporation Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CA3083341A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN110735176B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备配位化合物单晶或无定型物的方法
CN110606868A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备多肽或蛋白质单晶或无定型物的方法
CN110607553B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备粒径可调的药物或药物中间体单晶或无定型物的方法
CN110616463B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备有机半导体分子单晶或无定型物的方法
CN110607551B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种制备食品添加剂单晶或无定型物的方法
CN110735177B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种利用溶液冻结制备单晶或无定型物的方法
CN110607552B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种利用水溶液制备单晶或无定型物的方法
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS6041676B2 (ja) * 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
CA1265052A (en) * 1984-08-08 1990-01-30 Stanley J. Sarnoff Absorption enhancing agents
AU638251B2 (en) * 1989-05-24 1993-06-24 U.S. Bioscience, Inc. Method for protection from azt side effects and toxicity

Also Published As

Publication number Publication date
SK11395A3 (en) 1995-07-11
DE69333453D1 (de) 2004-04-22
NO20005775D0 (no) 2000-11-15
RU2125880C1 (ru) 1999-02-10
PL307298A1 (en) 1995-05-15
NO950343L (no) 1995-03-22
JPH08500104A (ja) 1996-01-09
PT655917E (pt) 2004-08-31
NO5775A (no) 1995-03-22
MX9304627A (es) 1994-04-29
EP0655917A1 (en) 1995-06-07
CA2120133C (en) 1998-06-09
HU227122B1 (en) 2010-07-28
CZ23095A3 (en) 1995-10-18
ATE261729T1 (de) 2004-04-15
CA2120133A1 (en) 1994-02-17
IS4060A (is) 1994-02-01
HK1010692A1 (en) 1999-06-25
NZ255182A (en) 1996-12-20
IL106540A0 (en) 1994-08-26
ES2215992T3 (es) 2004-10-16
US5591731A (en) 1997-01-07
NO309636B1 (no) 2001-03-05
AU4796693A (en) 1994-03-03
NO315691B1 (no) 2003-10-13
HU9500277D0 (en) 1995-03-28
PL178463B1 (pl) 2000-05-31
CN1070370C (zh) 2001-09-05
JP3503943B2 (ja) 2004-03-08
CZ284417B6 (cs) 1998-11-11
DK0655917T3 (da) 2004-07-26
SK283318B6 (sk) 2003-05-02
CN1307870A (zh) 2001-08-15
EP0655917A4 (en) 1995-08-02
CN1146428C (zh) 2004-04-21
HUT70191A (en) 1995-09-28
EP0655917B1 (en) 2004-03-17
IL106540A (en) 2000-02-17
CN1092980A (zh) 1994-10-05
AU681858B2 (en) 1997-09-11
SG47101A1 (en) 1998-03-20
NO950343D0 (no) 1995-01-30
DE69333453T2 (de) 2005-01-27

Similar Documents

Publication Publication Date Title
IS4060A (is) Aðferð til að framleiða kristallaða amifostínblöndu ásamt skammtaformum af kristölluðu amifostíni
MY110631A (en) Crystalline amifostine compositions and methods for the preparation and use of same.
DE3263573D1 (en) Pharmaceutically active phenylcarboxylic acid derivatives
SE8406081L (sv) Sett och komposition for framstellning av farmaceutiska preparat for oral administrering och med kontrollerad langtidsverkan
NO173015C (no) Analogifremgangsmaate til fremstilling av pyrido(1,2-a)pyrimidin-3-piperidinyl-1,2-benzisoksazoler
NO179582C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive hydroksamsyre- og N-hydroksyurinstoff-derivater
FI894899A0 (fi) Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi
NO176840C (no) Analogifremgangsmåte for fremstilling av 2,9-disubstituerte-4H-pyrido[1,2-aÅpyrimidin-4-oner
ES2103311T3 (es) Compuestos heterociclicos.
AR010984A1 (es) Nuevos esteres de la pleuromutilina, y el acido 1-azabiciclo-4- carbanilcarbanico; procedimiento para su preparacion y composicionesfarmaceuticas que los contienen.
HUP0100083A2 (hu) Piridingyűrűt tartalmazó kondenzált, tetraciklusos vegyületek, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
DE3767114D1 (de) Stabilisierte arzneimittel.
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
BR9807406A (pt) Formulação farmacêutica, e, processo para a preparação das mesmas
NO985202D0 (no) Anti-heliobacter pylori-preparater inneholdende 1-metylcarbapenemderivater
DE60031557D1 (de) Steroide, ihre herstellung , pharmazeutische zusammensetzungen mit ihnen und verwendungen dieser verbindungen
MY101266A (en) Pharmaceutical formulations
IT8719093A0 (it) Derivati di esteri dell'acido immidazol-1-il-carbossilico, procedimenti per la loro preparazione e composizioni fungicide che contengono il derivato come componente attivo.
HUT56716A (en) Process for producing pharmaceutical compositions suitable for preventing and treating autoimmune illnesses and skin diseases caused by heat and light radiation
ITMI912324A1 (it) Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche.
SE8700829L (sv) Farmaceutisk komposition
GEP20002241B (en) Polymorphs and Hydrated Forms of Lesopitron Dichlorohydrate, Methods for Its Preparation and Pharmaceutical Compositions Containing Same
IT1248525B (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.